The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents
Abstract
Cannabinoids are known to modulate GABAergic and glutamatergic transmission in cortical areas, the former via CB1 and the latter via a novel receptor. Pharmacological data demonstrate that several widely used cannabinoid ligands bind to both receptors, which may explain the inconsistencies in their behavioural effects. Earlier we showed that the cannabinoid antagonist SR-141716A affected behaviour in both CB1 knockout and wild-type animals, and its effect (anxiolysis) was different from that of CB1 gene disruption (anxiogenesis). In the present experiments, we studied the effects of the CB1 antagonist AM-251, and the cannabinoid agonist WIN-55,212-2 in wild-type as well as in CB1 knockout mice. CB1 knockout mice showed higher scores of anxiety-like behaviour than the wild-type animals in the elevated plus-maze. Selective blockade of CB1 receptors by AM-251 (0.3, 1 and 3 mg/kg) increased anxiety-like behaviour dose-dependently in the wild-type mice but had no effect in the knockouts. In wild types, the cannabinoid agonist WIN-55,212-2 (1 and 3 mg/kg) caused a decrease in anxiety-like behaviour, which was abolished by the CB1-selective antagonist AM-251 (3 mg/kg). The same agonist did not change plus-maze behaviour in CB1 knockout animals. These data demonstrate at the behavioural level that AM-251 and, at low concentrations, WIN-55,212-2, are selective ligands of the CB1 cannabinoid receptor in mice. Our studies on the behavioural effects of the cannabinoid antagonist SR-141716A and the CB1 antagonist AM-251 show that the CB1 and the novel cannabinoid receptor mediate anxiolytic and anxiogenic effects, respectively. This suggests that agonists of the former, or antagonists of the latter, are promising new compounds in the pharmacotherapy of anxiety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which in turn give rise to an anxious/depressive phenotype20, 21.”
From Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study (2013) · cites this paper as [21]
Citations
Cites
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Self-citationCannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218
Self-citationA review of the validity and variability of the Elevated Plus-Maze as an animal model of anxiety
Hogg, S. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02126-4 · Cited by 1,169
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. A., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,078
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 978
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
Katona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668
Cited by
Sorted by citations
Items 201–242 of 242
Gołyszny, M. J., Dragon, J., & Obuchowicz, E. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102564 · Cited by 4
da Silva, A. M. P., Lima, D. D. S., Souza, R. F., Lopes, V. H. P., Cardoso, L. J. C., Pinto, E. L. O., Gonçalves, O. R., Braga, C., Cal, H. D. S. R., Santos, D. H., et al. (2026) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2026.05.016 · Cited by 2
Komaki, A., Haghgooyan, A., Shahidi, ., Sarihi, A., & Salehi, I. (2014) · Avicenna Journal of Neuro Psych Physiology · doi:10.17795/ajnpp-24450 · Cited by 2
“Anxiety is increased by genetic and pharmacologic inhibition of the CB1 receptor (12, 29, 35, 62).”
BackgroundResultInfluentialRodrigues‐Ribeiro, L., Resende, B. L., Dias, M. L. P., Lopes, M. R., de Barros, L. L. M., Moraes, M. A., Verano‐Braga, T., & Souza, B. R. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-50624-6_6 · Cited by 3
Pakkhesal, S., Shakouri, M., Mosaddeghi-Heris, R., Kiani-Nasab, S., Salehi, N., Sharafi, A., & Ahmadalipour, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108799 · Cited by 3
Fotinos, A., Zhu, Y., Mao, L. L. J., Atassi, N., Zhou, E., Ahmad, S., Guan, Y., Berry, J. D., Cudkowicz, M., & Wang, X. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_51 · Cited by 2
Endocannabinoids, Stress, and Negative Affect
Berger, A. L., Henricks, A. M., Hill, M. N., & McLaughlin, R. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-57371-7_3 · Cited by 2
Endocannabinoid Signaling in the Habenula Regulates Adaptive Responses to Stress
Chen, Z., & Kenny, P. J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.08.001 · Cited by 2
Rodriguez, A. L., Qi, A., Han, A., Kling, H. E., Quitalig, M. C., Bender, A. M., Barbaro, L., Whomble, D. L., Lindsley, C. W., & Niswender, C. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104956 · Cited by 1
“CB 1 is a potential therapeutic target for indications including nausea [3], psychosis [4], anxiety [5], and pain [6].”
Cannabinoid Receptors Provide New Targets in Battling Anxiety
Stratton, H. J. (2012) · Biochemistry & Pharmacology Open Access · doi:10.4172/2167-0501.1000e139 · Cited by 1
“In recent years, the ECS has emerged as an important neuromodulatory system and has been heavily implicated in the regulation of anxious behavior [10-16].”
BackgroundEndocannabinoid Signaling and the Regulation of the Serotonin System
Haj‐Dahmane, S., & Shen, R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7940-6_11 · Cited by 1
“Indeed, results from behavioral studies, using various stress models, have shown that CB1 receptor agonists as well as drugs that increase eCB tone reduce stress response and exert anxiolytic-like effects (Kathuria et al. 2003; Haller et al. 2004; Marco et al. 2004).”
ResultInterdependenzen zwischen Financial Accounting und Business Reporting
(2009) · Gabler eBooks · doi:10.1007/978-3-8349-8175-2_11 · Cited by 1
Clinical decision making: a study to define educational objectives for resident physicians.
Hickam, D. H., & Cooney, T. G. (1986) · PubMed · Cited by 1
Pandolfo, P. (2007) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.021
de Bitencourt, R. M. (2008)
Carvalho, A. F., & Bockstaele, E. J. V. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7940-6_7
Role of the endocannabinoid system in human brain functions relevant for psychiatric disorders
Bossong, M. G. (2008) · Utrecht University Repository (Utrecht University)
Schulz, S. (2012) · State and University Library Bremen
Assini, F. L. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
CB1 Receptor Antagonist AM-251: Effect on Spatial Memory in Male Mice
Green, B. M. (2009) · California State University ScholarWorks (system-wide DSpace)
Role of the Cannabinoid Receptor Type 1 (CB1) in Synaptic Plasticity, Memory and Emotionality
Jacob, W. (2007) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.7230
The Role of LMO4 in the Regulation of Hippocampal and Amygdalar Synaptic Function
Qin, Z. (2013) · uO Research (University of Ottawa) · doi:10.20381/ruor-2709
J, H. L. G. (2014) · Biochemistry & Pharmacology Open Access · doi:10.4172/2167-0501.1000127
“Various reports point to involvement of CB1 antagonism (for example, by SR 141716), but not agonism, in anxiogenic effects [55-58].”
BackgroundKupferschmidt, D. A. (2012) · TSpace (University of Toronto)
Gamaleddin, I. (2013) · TSpace (University of Toronto)
Varga, B. (2017) · Eötvös Loránd Tudományegyetem · doi:10.15476/elte.2017.021
Self-citationBiomarkers of Agitation in Patients with Alzheimer's disease
Ruthirakuhan, M. T. (2019) · TSpace (University of Toronto)
Kline, T. B., Xu, C., Kreitzer, F. R., Hurst, D. P., Eldeeb, K., Wager‐Miller, J., Olivas, K., Hepburn, S. A., Huffman, J. W., Mackie, K., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115123
(2020) · Society for Neuroscience eBooks · doi:10.1523/hon.011002
Jacotte-Simancas, A., Molina, P. E., & Gilpin, N. W. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.30.542943
“A separate 3-way ANOVA revealed higher NBS scores in TBI rats relative to Sham Controls (F(1,71) = 6.”
BackgroundMethodBiomedical and public health studies on susceptibility to post-traumatic stress disorder
Jowf, G. I. A. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230906ga
Cannabinoid Receptor 1: The Neural Gatekeeper of Health and Disease
Goyal, A., Kumari, A., Verma, A., Bhatiya, S., & Yadav, H. N. (2025) · Current Neurovascular Research · doi:10.2174/0115672026403497250910124233
Endocannabinoids and the neurobiology of emotional states
Petrie, G. N., Lunge, A. R., Mayo, L. M., & Hill, M. N. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-13908-6.00021-9
Ün, B., Akarsakarya, Z., Özü, Ö., Ilgaz, N. S., Yılmaz, M. B., Seçilmiş, D., & Seçilmiş, M. (2026) · Brain and Behavior · doi:10.1002/brb3.71126
“…in low doses, possibly by modulating the brain’s endocannabinoid system, which plays a crucial role in regulating emotional responses and stress (Haller et al. 2004 ), it has also been shown that high doses of THC are often associated with increased anxiety and even paranoia, primarily due to…”
Tudella, G. C. N., Klostermann, A. U., Menegucci, G., Fernandes, J. V. A., & Pacheco, J. P. G. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09347-z
The role of the CB1 receptor in learning, memory and anxiety-like behaviors
Bolyard, L. L. (2009) · The Mathematics Enthusiast
Effects of cannabinoids and novelty on hippocampal electrophysiology
Amos, D. P. (2011) · UCL Discovery (University College London)
Metadata
- Authors
- Haller, J., Varga, B., Ledent, C., & Freund, T. F.
- Affiliations
- HUN-REN Institute of Experimental Medicine (HU)
- Université Libre de Bruxelles (BE)
- Corresponding author
- Haller, J.
- Venue
- Behavioural Pharmacology
- Published
- 2004-07
- Volume
- 15
- Issue
- 4
- Pages
- 299-304
- ISSN
- 0955-8810 (ISSN-L)
- OpenAlex
- W2009732294
- Cited by
- 241
- References
- 49
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 4 · 2023: 12 · 2022: 5 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 6 · 2015: 9 · 2014: 9 · 2013: 13 · 2012: 15
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Behavioural Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- National Institute of Mental Health (R01MH054671, MH54671)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- CB1 receptor, anxiolytic effects, anxiety-like behavior, CB1 knockout mice, AM251, WIN 55,212-2, SR141716A, CB1 agonists, elevated plus maze, GABAergic neurotransmission, glutamatergic neurotransmission
- MeSH terms
- Rimonabant, Animals, Behavior, Animal, Dose-Response Relationship, Drug, Drug Synergism, Male, Morpholines, Naphthalenes, Piperidines, Pyrazoles, Anti-Anxiety Agents, Mice, Knockout, Maze Learning, Receptor, Cannabinoid, CB1, Benzoxazines, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
